Article Text

Download PDFPDF

2022-RA-1192-ESGO NOGGO ov44 – PERCEPTION What is the role of immunotherapy in low grade ovarian cancer? A NOGGO phase II trial of pembrolizumab in combination with chemotherapy in recurrent low-grade serous ovarian cancer
  1. Jacek Grabowski1,
  2. Lea-Jean Pietzke2,
  3. Dario Zocholl3,
  4. Philipp Harter4,
  5. Florian Heitz4,
  6. Julia Welz4,
  7. Sabrina Kaiser4,
  8. Tjadina Arndt1,
  9. Radoslav Chekerov1 and
  10. Jalid Sehouli1
  1. 1Department of Gynecology with Center for Oncological Surgery, Charité-University Medicine of Berlin, Berlin, Germany
  2. 2North-Eastern German Society of Gynaecological Oncology (NOGGO), Berlin, Germany
  3. 3Institute of Biometry and Clinical Epidemiology, Charité – University Medicine of Berlin, corporate member of Free University of Berlin and Humboldt University of Berlin, Berlin, Germany
  4. 4Department of Gynecology and Gynecological Oncology, Kliniken Essen-Mitte, Essen, Germany


Introduction/Background Within the group of invasive epithelial ovarian cancers, low-grade serous ovarian cancer (LGSOC) is a minority. Recent studies have revealed that LGSOC is only moderately sensitive to chemotherapy. No other agents have been approved in LGSOC since the implementation of bevacizumab several years ago. New therapeutic combinations with current chemicals are in high demand to improve the response rate and prognosis in this group of patients. Immune checkpoint inhibitors are a new treatment option that has shown to be successful in a variety of cancers as well as in a subset of ovarian cancer patients. The standard chemotherapy will be administered with pembrolizumab in recurrent LGSOC cases with a treatment free interval (TFI) of more than 6 months after the last platinum-based chemotherapy. There have been no comparable studie completed or planned to the authors knowledge. If our trial demonstrates the efficacy of pembrolizumab in LGSOC, it will serve as a signal and urge for future clinical trials in this rare condition.

Methodology This is a multi-center, single-arm phase 2 study evaluating pembrolizumab therapy in recurrent LGSOC cases in combination with platinum-based chemotherapy (carboplatin plus pegylated liposomal doxorubicin or carboplatin plus gemcitabine) and as maintenance. This clinical trial is open to LGSOC patients who have progressed or recurred at least six months after the last platinum-containing treatment. The perimary objective is to determine the rate of progression-free survival (PFS) after 12 months. The trial will follow Simon’s two-stage design, with a total enrollment of up to 33 patients. In the first phase 18 patients will be enrolled and if at least 5 patients show PFS after 12 months the study is going to be continued with an additional 15 patients. The trial is claimed successful, if at least 11 patients show PFS after 12 months.

Results -

Conclusion -

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.